AI Portfolio Summary
In 2025 Q4, GENERAL ATLANTIC, L.P. maintained a portfolio of 17 distinct positions. The most significant new addition to the portfolio was NURIX THERAPEUTICS, which now represents 3.23% of the total fund value. They heavily accumulated shares in CHIME, increasing their position by 10.7%. Conversely, GENERAL ATLANTIC, L.P. completely exited their position in AKERO THERAPEUTICS.
Total Positions
17
Quarter
2025 Q4
Top Holding
DLO (23.0%)
Top 10 Concentration
99.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-17 of 17
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
DLO
DLOCAL
|
Technology | 22.97% | 20.00% |
#1
Prev: #1
|
9.2 | no change | no change |
P
S
|
46,656,695 | $659,725,667 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CHYM
CHIME
|
Technology | 18.63% | 11.63% |
#2
2
Prev: #4
|
9.5 | 2,050,923 | 10.7% |
P
S
|
21,259,683 | $535,106,221 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XP
XP, INC
|
Financial Services | 12.93% | 14.40% |
#3
1
Prev: #2
|
5.2 | -2,818,600 | -11.0% |
P
S
|
22,699,133 | $371,584,807 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKT
ALKAMI
|
Technology | 9.63% | 8.94% |
#4
1
Prev: #5
|
3.9 | no change | no change |
P
S
|
11,991,480 | $276,643,444 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALHC
ALIGNMENT HEALT...
|
Healthcare | 9.05% | 12.72% |
#5
2
Prev: #3
|
3.8 | -11,119,494 | -45.8% |
P
S
|
13,167,733 | $260,062,727 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 7.80% | 3.47% |
#6
3
Prev: #9
|
5.2 | 338,500 | 13.7% |
P
S
|
2,812,928 | $224,049,715 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHVS
PHARVARIS
|
Healthcare | 7.76% | 6.02% |
#7
1
Prev: #8
|
3.1 | no change | no change |
P
S
|
8,031,252 | $222,867,243 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 5.33% | 7.05% |
#8
1
Prev: #7
|
2.2 | -3,564,103 | -36.8% |
P
S
|
6,117,715 | $153,004,052 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 3.23% | — |
#9
Prev: #—
|
3.3 | 4,897,159 | no change |
NEW
|
4,897,159 | $92,899,106 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWCZ
EUROPEAN WAX CE...
|
Consumer Defensive | 1.64% | 1.57% |
#10
2
Prev: #12
|
0.7 | no change | no change |
P
S
|
13,110,492 | $47,197,771 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RSKD
RISKIFIED
|
Technology | 0.92% | 0.75% |
#11
2
Prev: #13
|
0.4 | no change | no change |
P
S
|
5,324,998 | $26,465,240 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GROV
GROVE COLLABORA...
|
Consumer Defensive | 0.09% | 0.11% |
#12
4
Prev: #16
|
0.0 | no change | no change |
P
S
|
2,474,859 | $2,722,345 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BULL
WEBULL
|
Technology | 0.01% | 3.20% |
#13
3
Prev: #10
|
0.3 | -7,148,051 | -99.3% |
P
S
|
50,816 | $394,840 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AKRO
AKERO THERAPEUT...
|
Healthcare | 0.00% | 8.17% |
Sold All 😨
(Was: #6) |
0.3 | -5,733,989 | -100.0% |
CLOSED
|
— | $— | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RPRX
ROYALTY PHARMA
|
Healthcare | 0.00% | 1.59% |
Sold All 😨
(Was: #11) |
0.3 | -1,500,000 | -100.0% |
CLOSED
|
— | $— | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADAG
ADAGENE
|
Healthcare | 0.00% | 0.23% |
Sold All 😨
(Was: #14) |
0.3 | -3,782,339 | -100.0% |
CLOSED
|
— | $— | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALMS
ALUMIS
|
Healthcare | 0.00% | 0.16% |
Sold All 😨
(Was: #15) |
0.3 | -1,297,530 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-17 of 17 holdings